Anvisa – Changes in RDC 821/2023 and IN 258/2023

Many pills and tablets of various types displayed together in a single image

Anvisa – Informs the updates on the RDC 53/2015 and IN 258/2023 on qualified impurities is published
Anvisa (National Health Surveillance Agency) informs that RDC 821/2023 and IN 258/2023 was published on November 1, simplifying the qualification of impurities in pharmaceutical products. Listed impurities do not require a specific addition, while unlisted impurities require documentation for analysis. 

Read more here

If you need more information for drug regulatory issues, ELS can help with our registration services for your products.

Contact your local ELS consultant or via email info@elssolutions.pt

ELS Group

ELS Group brings together a team of highly specialized professionals with proven experience in regulatory frameworks and compliance in the pharmaceutical field.

Strategic consulting for the pharmaceutical, healthcare, food, and medtech industries.

Rely on experts to support your regulatory decisions and accelerate the growth of your products safely and efficiently.

I want to speak to a Specialist

Strategic consulting for the pharmaceutical, healthcare, food, and medtech industries.

Experts in pharmaceutical consulting, regulatory strategy, and market access to support your company with safety, compliance, and efficiency. Talk to a consultant.

I want to speak to a Specialist